



## ATA 2010 Spring Meeting in Minneapolis to focus on 'Personalized Medicine'

Internationally recognized thyroid disease experts will meet to discuss "Thyroid Disorders in the Era of Personalized Medicine" May 13 – 16 in Minneapolis, Minnesota at the American Thyroid Association's (ATA) ([www.thyroid.org](http://www.thyroid.org)) Spring Meeting to be held at the Minneapolis Hyatt Regency Hotel.



With the incidence of thyroid cancer rising for more than a decade and hypothyroidism increasingly recognized

as being associated with comorbidities, researchers and clinicians are recognizing that new approaches, new treatments and more preventive measures are needed. Personalized medicine, the theme of the spring meeting, may hold

many of the necessary keys.

"Personalized medicine is a concept that recognizes that a 'one-size-fits-all' medicine is no longer how medicine should

*continued on page 5*

## Corporate Leadership Council

Under the leadership of Steven I. Sherman, Chair of the ATA Development Task Force, the American Thyroid Association has organized an initial, organizational meeting to establish a Corporate Leadership Council (CLC). The mission of this new initiative will be to provide a forum for open communication between the ATA and the community of corporations that share interest in thyroid health and biology.

The ATA recognizes that strengthening relationships with our corporate partners and supporters will greatly enhance our

*continued on page 10*



## Women in Thyroidology

American Thyroid Association

Women in Thyroidology (WIT) is the first ATA group to launch an online Social Media group for the purpose of professional interactions and collegial networking. There will be both social and professional components to the NING site: photos of members, scientific slides to discuss, cooperative ATA projects, meetings to plan, and potential coordination of meeting accommodations and attendance. The networking site is open to ATA

*continued on page 11*

## President's Comments

### "Cheese" and the ATA



I have spent much of my life "chasing cheese."\*

Now and then, I have had

the opportunity to move the cheese myself. But mostly, I have been trying to find the cheese and, when I find it gone, I have to search around and detect where it has been moved to. I then have to analyze why it has moved and whether its new placement is superior or not.

It so happens I like cheese. Nothing finishes a meal better than a good cup of espresso coffee and a piece of

*continued on page 4*

## IN THIS ISSUE

**Secretary's Report**  
Page 2

**Treasurer's Report**  
Page 3

**Editor's Corner**  
Page 5

**ATA Member Updates**  
Pages 7

**ATA Upcoming Meetings**  
Pages 7

**Annual Fund Donors**  
Pages 8–9

**"Find a thyroid specialist"**  
Page 10

## Important ATA Member Notices — visit [www.thyroid.org](http://www.thyroid.org) for more information

- ATA 2010 Spring Meeting, May 13 – 16 in Minneapolis, Minnesota
- Reminder to Members — please take a few moments to update your profile/contact information by going to 'Edit Member Profile' in the Members' Only Section at [www.thyroid.org](http://www.thyroid.org).



# ATA Signal

**Editor**

James A. Fagin, MD

**Managing Editor**

Barbara (Bobbi) R. Smith, CAE

**Officers and Directors 2009–2010****President**

Terry F. Davies, MD (2009-2010)  
New York, New York

**Secretary/Chief Operating Officer**

Richard T. Kloos, MD (2007-2011)  
Columbus, Ohio

**Treasurer**

David H. Sarne, MD (2007-2013)  
Chicago, Illinois

**President-Elect**

Gregory A. Brent, MD (2009-2010)  
Los Angeles, California

**Past-President**

Kenneth D. Burman, MD (2009-2010)  
Washington, DC

**Directors**

Antonio C. Bianco, MD, PhD (2006-2010)  
Miami, Florida

Alan P. Farwell, MD (2006-2010)  
Boston, Massachusetts

Michael T. McDermott, MD (2006-2010)  
Aurora, Colorado

Ian D. Hay, MD, PhD (2007-2011)  
Rochester, Minnesota

R. Michael Tuttle, MD (2007-2011)  
New York, New York

James A. Fagin, MD (2008-2012)  
New York, New York

M. Carol Greenlee, MD (2008-2012)  
Grand Junction, Colorado

Peter A. Kopp, MD (2009-2013)  
Chicago, Illinois

Elizabeth N. Pearce, MD (2009-2013)  
Boston, Massachusetts

**Executive Director**

Barbara R. Smith, CAE

**Published by the**

American Thyroid Association  
6066 Leesburg Pike, Suite 550  
Falls Church, Virginia 22041  
Phone: 703 998-8890  
Fax: 703 998-8893  
E-mail: [bsmith@thyroid.org](mailto:bsmith@thyroid.org)  
Web: [www.thyroid.org](http://www.thyroid.org)

Please notify the ATA of changes  
in contact information.

Copyright 2010

American Thyroid Association

## Secretary's Report



The ATA is alive, well, and actively serving our mission. Here, I briefly report good news and a few achievements by our association.

Not too long ago, I wrote the membership to warn of how the financial crisis was going to impact the ATA. As treasurer David Sarne reviews in his report, the ATA took action in multiple ways. In the end, our 2009 Annual Meeting income was 95 percent what we had budgeted while our expenses were dramatically reduced. Thus, the Annual Meeting returned its

Many have contributed to this outreach, but special thanks should be extended to Stephanie Fish, Greg Brent and Vic Bernet for their efforts regarding our trainees and the Internet services that we provide.

The ATA remains active in public health and safety. On March 18, 2010, Edward J. Markey (D-MA), Chairman, Subcommittee on Energy and Environment, Energy and Commerce Committee, released a report entitled "RADIOACTIVE ROULETTE: How the Nuclear Regulatory Commission's Cancer Patient Radiation Rules Gamble with Public Health and Safety" ([http://](http://markey.house.gov/docs/STAFF_REPORT_031810_FINAL_with_crest.pdf)

## This fall the ITC meeting in Paris promises to be an outstanding venue for the gathering of the world's experts in thyroid disease.

needed profit as we prepare for 2010 when our Association forgoes an Annual Meeting (and its income) in exchange for the highly memorable and educational experience of the International Thyroid Congress (ITC).

This fall the ITC meeting in Paris promises to be an outstanding venue for the gathering of the world's experts in thyroid disease. You are encouraged to register and make your travel arrangements now.

In President Terry Davies' report you will read about change. The ATA membership has certainly been changing. We have grown to 1268 current members with one third of members female. These statistics become more interesting when one looks at age. For members 40 years of age or younger, 58 percent are female. These demographics provide insight into the future of the ATA, and likely into endocrinology in general.

The ATA recognizes that the trainees of today are the keys to our future and has invested extensively in recruitment to include free ATA Associate membership, the "Fellow's Corner" on the Web, and the "Fellow's Track" in our meetings.

[markey.house.gov/docs/STAFF\\_REPORT\\_031810\\_FINAL\\_with\\_crest.pdf](http://markey.house.gov/docs/STAFF_REPORT_031810_FINAL_with_crest.pdf)). This report was widely covered in the news, including in USA Today ([http://www.usatoday.com/news/health/2010-03-18\\_radcancer18\\_ST\\_N.htm?csp=usat.me](http://www.usatoday.com/news/health/2010-03-18_radcancer18_ST_N.htm?csp=usat.me)).

The report is critical of the Nuclear Regulatory Commission and includes accusations of lack of oversight as well as ignoring reported problems and recommendations. The report expresses strong concern over the allowance of radioactive patients to stay in hotels. With a joint statement the ATA responded to this report along with The Endocrine Society, the Society of Nuclear Medicine, and the American Association of Clinical Endocrinologists. We expressed that we believe the current procedure, based on all available scientific evidence, is safe for patients, their families and the public when radiation safety instructions are followed. Related to this topic, Carol Greenlee led a task force to examine current scientific evidence for any potential risks to the public from I-131

*continued on page 6*

## The Glass is Half Full



Just over a year ago, the ATA was facing a crisis. Attendance at the Thyroid Cancer Workshop was below expectations. Failure to fill our room block as well as reduced industry support created an unanticipated financial loss. An outstanding spring meeting on pregnancy and the thyroid also failed to meet financial expectations. Between the sluggish economy and national trends complicating the relationships between industry and professional organizations, it became clear that we had to anticipate less financial support from industry. With our dues already collected and industry financial support reduced, the board of directors had to make some difficult decisions to avoid a similar outcome for our annual meeting.

When the ATA board and staff reevaluated our plans for the annual meeting, every expense was reconsidered in an effort to identify savings that would not compromise the quality of the meeting. The meeting registration fee was increased above our historical norms, but was not considered inconsistent with charges for other professional meetings. The result of those efforts was a meeting that met both our educational and financial expectations.

We also reevaluated our plans for 2010 and the remainder of 2009. An additional planned Thyroid Cancer Workshop was cancelled. Expenses were re-examined to find ways to reduce or eliminate unnecessary expenses. While we searched for other sources of revenue, we raised the dues for 2010 recognizing that we have to bear the costs for our activities and we can no longer rely on industry for as much support as they provided in the past.

### ATA is Making a Difference

This past fall, our revised thyroid nodule and cancer guidelines were published. They have rapidly become the standard in multiple disciplines and have been featured at meetings of other professional societies. New or revised guidelines are in development for thyroid and pregnancy, hyperthyroidism, and anaplastic carcinoma.

In just the past few weeks, the ATA has responded to issues and requests for our expertise on risks to the thyroid from a new drug approved by the FDA, risks to the public from outpatient radioactive iodine therapy, drug equivalence and bioequivalence, and on potential supply issues of recombinant TSH and radioactive iodine.

### What You Can Do to Help

**Use our hotel when attending our meetings** — In exchange for our attendees booking hotel rooms, we do not pay for our meeting space. We recognize alternative housing is often available to individuals at a lower cost, but when we do not meet our room commitments, we face significant financial penalties.

**Bring a friend** — Bringing new attendees to our meetings will save both of you on the registration fee and helps introduce the ATA to prospective members.

**Support trainees and fellows** — They are the future of our organization. Your contributions to fund travel and research support for our young members is vital for our continued growth.

**Apply for a no-fee ATA Credit Card from Capital One** — Use the card once, and Capital One donates \$50 to the ATA. The ATA also receives 1-2% of the value of all your purchases. If you are planning to attend the ITC in Paris, most credit cards will now charge you a fee of 2-3 percent of the value of all purchase abroad, but there is no such fee on the Capital One Card.

**Pay your dues on time** — Staff spends the better part of six months collecting dues from 20% of our membership. Their valuable time is better spent on programs that advance education and research for thyroidology and service to patients.

**Participate on a Committee** — These groups do much of the work of the ATA. By participating, you help advance the work of the association and also develop closer ties with other ATA members.

**Share your thoughts and suggestions** — Let the Board, officers or staff know what you are thinking. We continue to look for opportunities to improve our activities and operations.

The ATA is making a difference. With your continued support, we can continue to fulfill our mission for thyroid education, research, patient support and public advocacy.

See you in Minneapolis!

David H. Sarne  
Treasurer

**CLINICAL  
THYROIDOLOGY  
ONLINE**

**Editor: Ernest L. Mazzaferri, MD**

CLINICAL THYROIDOLOGY, published online monthly, is a broad-ranging look at the clinical and preclinical thyroid literature. The Editor searches the world literature for excellent thyroid studies and then summarizes them and provides expert commentary.

well-matured Brie. But losing your cheese and chasing cheese can be painful. I am of course playing with the word "cheese" rather than the word "change." In my experience, people who cope with change are by far the more successful; but as we get older we start to have opinions. Having opinions about change does not always go down well with everyone - in particular the cheese movers. Let's take some examples.

As the past editor of *Thyroid* I was in place when we converted from paper submissions to electronic submissions. One day we had hundreds of files to handle and store and retrieve and lose. The next month, they were history. Gone. Everything was handled digitally. At the time it was painful.

There was a steep learning curve. But now? My goodness. We wouldn't dream of submitting paper to anything! But the change made more work and responsibility for the editor - just as I feared.

The same with electronic medical records. A steep learning curve is followed by the realization that paper charts are totally unacceptable, unreadable and often misplaced or missing parts. But again - more work for the physician - the data entry - the computer generated correspondence replacing your assistants, etc.

Now, how does this relate to the American Thyroid Association? Change is upon us. Great changes are upon us. The cheese has moved. And we can chase it and find it again and enjoy it, or we can turn away and never find the cheese again.

What are the changes? Let's start with commercial interactions. The ATA can no longer be immune from criticism that it relies too much on pharmaceutical and other commercial support for its activities. Such support is no longer politically acceptable. The academic medical centers have even stopped us giving lectures directly for such commercial enterprises. Whether we think this is good or bad, it is now a "no-no." This means that members have to pay their way at the ATA's Annual Meeting, leading to increased registration fees. But it is also incumbent upon

the officers of the ATA to keep the cost of the meetings as low as possible and to search for other sources of income. This is an important topic on which members need to make themselves heard.

Another huge change is the use of the ATA Web Site and the Internet in general. The Internet is so effective that I wonder whether we should be sending anything by mail anymore - the cheese has moved. The time for membership mailings, meeting announcements, and even printed journals is rapidly vanishing. If you want a printed version then print it off the Web at home or in your office. The success of *Clinical Thyroidology*, with almost 5000 email distributions, is direct evidence of this sea change.

And what about meetings? Now you can meet on the Web with video support, participate in conferences large and small, even have video visits to the clinic or laboratory. This will never replace real people meetings entirely, but it does mean that many smaller gatherings will start to appear as Web-based. So, the cheese is moving at the ATA and not just in our own lives. And the people who do best in this situation are the cheese movers rather than the cheese followers. The ATA needs to invest heavily in the future by becoming more and more Web-based and by keeping abreast of technical advances. I see no reason why *Thyroid* could not be available on the Nook or the "Kindle E" readers, or why *Signal* should not have an "app" on my Blackberry. Cheese is good for all of us..... as long as we do not have too much.

Be sure to join us in Minneapolis.

Sincerely,



Terry F. Davies, MD  
ATA President

\* "Who Moved My Cheese?" is a best-selling book (1998) by Spencer Johnson, MD.

The Internet is so effective that I wonder whether we should be sending anything by mail anymore - the cheese has moved.

## 2010 ATA Spring Meeting — Saturday, May 15 — Early Riser Symposium

**6:15 AM – 8:00 AM Supported by an educational grant from Abbott Laboratories, Inc.**

Personalizing Selections in the Area of Thyroid Hormone Disease

Chair: Lynn A. Burmeister

Is Your TSH Normal? Well, That Depends... Selecting Patients and TSH Targets for LT<sub>4</sub> Therapy

John C. Morris

Thyroid Hormone Analogues: Applications for Cardiovascular and Lipid Outcomes

Irwin L. Klein

Recombinant hTSH vs Thyroid Hormone Withdrawal for Remnant Ablation and Thyroid Cancer Treatment

Victor J. Bernet





### Corporate relations of the ATA

In this issue, Rick Kloos and David Sarne, our secretary and treasurer, discuss the impact of decreased support from pharmaceutical industry on the financial situation of the ATA.

There is a clear expectation from the general public that physicians, clinical investigators, biomedical scientists and the organizations that represent them show full transparency in their relationships with pharmaceutical companies. We must do this without demonizing our colleagues in industry, whose contributions to health care and the progress of science should not be minimized. Like it or not, we are in a symbiotic relationship, and the much vaunted push towards translational research will not materialize to its full potential unless the interactions between academia and industry are healthy, collaborative and conducted in an ethical manner. However, most of us breathe easier when our motivations and primary interests

are clear for all to see, and not subject to question. As part of this process, the relationship of the ATA with its traditional corporate supporters has been restructured. This requires that we all take responsibility for a larger share of our expenses. It is therefore only fitting in these leaner times that we should focus the organization on the areas that are of greatest value to our members.

We hope to see you all in Minnesota at the Spring Meeting of the ATA, where you will have a chance to participate in an outstanding scientific program, and to contribute and help shape a broad range of initiatives that our organization is engaged in.

James A. Fagin, MD  
Editor, *Signal*

### ATA Spring 2010 Meeting *continued from page 1*

be practiced in the twenty-first century,” says ATA president Terry F. Davies, MD. “Personalized medicine focuses on individualizing therapy based on a person’s genetic makeup as well as other, non-genetic factors.”

Since the human genome was sequenced in 2000 and subsequent advances have been made in discovering the genetic basis for many diseases and disorders, medicine has been in the midst of the “personalized medicine” revolution. The variety of thyroid diseases - from hypothyroidism to thyroid cancer - may be more treatable and preventable when the advancements making personalized medicine possible are applied.

The ATA’s spring meeting brings together those experts in thyroid diseases who are working at the frontier intersections of the genetic and molecular bases of thyroid diseases as well as the genetic and molecular-based potentials for treatment.

“Traditionally, medicine tried to group diseases and their treatments into unified categories. However, the same disease will have different manifestations, complications, and responses to therapy in different individuals, and therefore, there is a need to individualize therapy for patients,” says



**Minneapolis Spring 2010 ATA  
Program Chairs: Virginia Sarapura  
and Yaron Tomer**

**For meeting details, please log on to:  
[www.thyroid.org/ann\\_mtg/2010\\_spring/index.html](http://www.thyroid.org/ann_mtg/2010_spring/index.html)**

**Thyroid Disorders in the Era of Personalized Medicine  
May 13–16, 2010 • Minneapolis, Minnesota**

Yaron Tomer, M.D., F.A.C.P, meeting co-chair and director of autoimmune genetics at Mount Sinai Institute for Personalized Medicine.

The ATA spring meeting also aims at introducing personalized medicine to practicing thyroidologists interested in exploring its potentials.

“The meeting will emphasize both general concepts in personalized medicine as well as specific issues relating to thyroid diseases,” says meeting co-chair Virginia Sarapura M.D.

According to Dr. Davies, genetic and biomarker testing

will offer information critical for patient care decisions, disease susceptibility and progression as well as potentially predict positive or adverse responses to drug therapy.

ATA Spring 2010 Meeting Speakers will present current research on the potential for employing personalized medicine in treating thyroid cancer; hypothyroidism; hyperthyroidism; Graves’ disease; thyroid issues in pregnancy; pediatric thyroid disease; and implementing pharmacogenomic screening to prevent drug reactions.

For meeting details, please log on to: [www.thyroid.org/ann\\_mtg/2010\\_spring/index.html](http://www.thyroid.org/ann_mtg/2010_spring/index.html)

therapy of thyroid cancer and hyperthyroidism. The result is a document of best practice recommendations that has been submitted to *Thyroid*<sup>®</sup> for publication. These best practice recommendations are intended to assist physicians who treat patients with radioiodine, to ensure that such treatments comply with federal regulations, and to minimize radiation exposure to family members and the general public. Although harm from radiation exposure to contacts of patients treated with radioiodine has not been shown, these recommendations follow the principle of reducing radiation exposure to levels as low as reasonably achievable (ALARA). These recommendations are intended to provide clear, uniform, practical recommendations that recognize the need for flexibility in individual circumstances. The release of our joint statement and best practices recommendations demonstrate that the ATA is a vocal leader serving the interests of our patients, their families, and the public.

The ATA interacts regularly with the U.S. Food and Drug Administration (FDA) whose mission is to protect the public health by assuring the safety, efficacy, and security of human and veterinary drugs, biological products, medical devices, our nation's food supply, cosmetics, and products that emit radiation. To this end, the ATA corresponded with the FDA on March 27, 2010 in a letter signed by ATA President Terry Davies as we learned that the availability of Thyrogen<sup>®</sup> (recombinant human thyrotropin, manufactured by Genzyme, Inc.) may be compromised due to manufacturing problems that have been identified by the FDA ([http://www.businesswire.com/portal/site/genzyme/index.jsp?ndmViewId=news\\_view&ndmConfigId=1019673&newsId=20100324005866&newsLang=en](http://www.businesswire.com/portal/site/genzyme/index.jsp?ndmViewId=news_view&ndmConfigId=1019673&newsId=20100324005866&newsLang=en)). The ATA expressed support for the efforts of the FDA to ensure that the Thyrogen<sup>®</sup> we give our patients is as safe as possible. We also expressed that the FDA must recognize that Thyrogen<sup>®</sup> and thyroid hormone withdrawal are not simply interchangeable; that some patients are at higher risk of complications from hypothyroidism given significant underlying medical or psychiatric conditions, and that some patients simply cannot mount an endogenous rise in TSH.

**These best practice recommendations are intended to assist physicians who treat patients with radioiodine, to ensure that such treatments comply with federal regulations, and to minimize radiation exposure to family members and the general public.**

We believe it important that the FDA recognize these issues as they make decisions affecting the availability of Thyrogen<sup>®</sup> in the near future. The ATA offered our independent expertise that would in any way be helpful to this process.

On April 13, 2010 the Pharmaceutical Science and Clinical Pharmacology Advisory Committee of the FDA received presentations from the Office of Generic Drugs and discussed two bioequivalence (BE) topics relevant to generic drug approval: (1) revising the BE approaches for critical dose drugs; and (2) the use of partial area under the curve for the evaluation of abbreviated new drug applications for products with complex pharmacokinetic profiles. In response, the ATA requested that Vic Bernet speak before the Committee. Our submitted written materials included the position that the current methodology to determine levothyroxine bioequivalence is inadequate. We suggested that additional measures beyond thyroxine levels should be included in the analysis of levothyroxine bioequivalence – especially the inclusion of TSH measurements as a more sensitive measure of pharmacodynamics.

The activities of the ATA happen because of its dedicated membership. The ATA could not afford to pay our volunteer members even the minimum wage for the hours that they “donate” to the ATA. The ATA staff, the Executive Committee, the Board of Directors, Committee chairs, Committee volunteers, and Task Force members work to anticipate the needs of the Association, take work upon them, and accept responsibility to complete their tasks. These talented and committed volunteers make all of this happen by working early in the morning, in between patients, late at night, and on weekends, holidays, and during vacations. I am grateful for the skills and wisdom that they share with me in the service of your ATA.

Sincerely,



Richard T. Kloos, MD  
ATA Secretary/Chief Operating Officer



## ATA Member Updates

### ATA Past-President Chin Named Executive Dean for Research at Harvard

**William W. Chin, MD**, is Harvard Medical School (HMS) executive dean for Research, a newly created senior position with overarching responsibility for biomedical research at HMS. As a senior member of the leadership team, Dr. Chin will spearhead efforts to design and implement a vision for research at HMS, with special emphasis on interdisciplinary research that crosses departmental and institutional boundaries. Dr. Chin is past-president of the American Thyroid Association.

### ATA Past-President Ridgway Named Editor-in-Chief of Endocrine Reviews

**E. Chester Ridgway, MD**, professor of medicine and interim chairman of the Department of Medicine at the University of Colorado Denver, has been named editor-in-chief elect of Endocrine Reviews, a journal of The Endocrine Society. Endocrine Reviews publishes bimonthly comprehensive, authoritative and timely review articles balancing both experimental and clinical endocrinology themes. "It is an honor to lead such a prestigious scientific journal," said Dr. Ridgway. Dr. Ridgway is a past-president of the American Thyroid Association and The Endocrine Society. His term as editor-in-chief of Endocrine Reviews will begin in January 2011.

### ATA Past-President Wartofsky Serves as Editor-in-Chief of the Journal of Clinical Endocrinology & Metabolism

**Leonard Wartofsky, MD**, chairman of the Department of Medicine at Washington Hospital Center in Washington, D.C., is the editor-in-chief of The Journal of Clinical Endocrinology & Metabolism (JCEM), a journal of The Endocrine Society. JCEM provides the latest in-depth coverage of new developments enhancing the understanding, diagnosis and treatment of endocrine and metabolic disorders. "I am honored by the opportunity to lead JCEM ...," said Dr. Wartofsky. Dr. Wartofsky is past-president and past-secretary of the American Thyroid Association and past-president of The Endocrine Society.

## Upcoming Meetings

### American Thyroid Association SPRING 2010 Thyroid Disorders in the Era of Personalized Medicine

May 13–16, 2010  
Hyatt Regency Minneapolis  
Minneapolis, Minnesota  
Phone: (703) 998-8890  
Fax: (703) 998-8893  
Website: [www.thyroid.org](http://www.thyroid.org)

The Endocrine Society  
ENDO 2010  
June 19–22, 2010  
San Diego, California  
Website: [www.endo-society.org](http://www.endo-society.org)

### 14th International Thyroid Congress

Co-sponsored by  
the American Thyroid Association  
September 11–16, 2010  
Paris, France  
E-mail: [itc2010@mci-group.com](mailto:itc2010@mci-group.com)  
Website: [www.itc2010.com](http://www.itc2010.com)

### 14th Asia-Oceania Congress of Endocrinology

December 2–5, 2010  
Kuala Lumpur, Malaysia  
Website: [www.aoce2010.com](http://www.aoce2010.com)  
Email: [aoce2010@console.com.my](mailto:aoce2010@console.com.my)

Visit the ATA website at [www.thyroid.org](http://www.thyroid.org) for updates and information on all upcoming ATA events.

# 14<sup>th</sup> INTERNATIONAL THYROID CONGRESS

PARIS, PALAIS DES CONGRÈS • 11-16 SEPTEMBER 2010



# Thank You to Our Annual Fund Donors 2010

## 2010 ATA Annual Fund Donors

137 ATA members have donated a total of \$31,430 to the 2010 Annual Fund since October 1, 2009. These funds are dedicated to support of the ATA Research Grant program, the ATA Fellows Program: supporting attendance at our annual meeting, providing travel grants and a specialized educational track customized for their benefit, and to ATA Patient Education online.

Donations received between October 1, 2009 and April 8, 2010.

Peter Arvan, MD, PhD	Jeffrey R. Garber, MD	Edward Merker, MD
Ernest O. Asamoah, MD, FACP, FACE, FRCP	David F. Gardner, MD	Jorge H. Mestman, MD
Fuad S. Ashkar, MD	Romulo Garza, PhD	Mohammed Moinuddin, MD
Barbara A. Baker, MD	Eric M. Genden, MD	John C. Morris, III, MD
Charles P. Barsano, MD, PhD	Colum A. Gorman, MB, ChB	Brett L. Moses, MD
Luigi Bartalena, MD	Scott P. Grady, MD	Rosalie Naglieri, MD
Richard A. Becker, MD	William L. Green, MD	Shigenori Nakamura, MD
Diego Bellabarba, MD	Yannis S. Guerra, MD	Muriel H. Nathan, MD, PhD
Salvatore Benvenga, MD	Abdullah A. Gunaid, MD	Amy L. O'Donnell, MD
Victor J. Bernet, COL, MC, MD	Celeste B. Hart, MD	Yolanda C. Oertel, MD
Trine Bjoro, MD, PhD	Bryan R. Haugen, MD	Omolola B. Olajide, MD
Manfred Blum, MD	Jerome M. Hershman, MD	Beatriz R. Olson, MD, FACP
Salah-Eddine Bouyoucef, MD, PhD	Jacqueline Ann Hobbs, MD, PhD	Furio Pacini, MD
Glenn D. Braunstein, MD	Joseph G. Hollowell, Jr., MD, MPH	Johanna A. Pallotta, MD
Lewis E. Braverman, MD	Helmuth Huber, MD	Louis N. Pangaro, MD
Rosalind S. Brown, MD, CM	Sissy M. Jhiang, PhD	Paschalis G. Pantos, MD
Eric Carnell, MD	Yoshio Kasuga, MD, PhD	Young Joo Park, MD, PhD
Maria Regina Castro, MD	Richard T. Kloos, MD	Elizabeth N. Pearce, MD
Boris Catz, MD	Leonard D. Kohn, MD	Kimberly A. Placzkowski, MD
Ramana V. Chennubhotla, MD	Peter A. Kopp, MD	Eduardo A. Pretell, MD
Orlo H. Clark, MD	Annie WC Kung, MD	Richard A. Prinz, MD
David S. Cooper, MD	Hideo Kurihara, MD	Gregory W. Randolph, MD
Wolfgang H. Dillmann, MD	Stephen H. LaFranchi, MD	Basil Rapoport, MB, ChB
Catherine A. Dinauer, MD	P. Reed Larsen, MD	Sara L. Richer, MD
Joseph J. DiStefano, III, PhD	Jennifer E. Lawrence, MD	E. Chester Ridgway, MD
Robert B. Doll, Jr., MD	John H. Lazarus, MD	Matthew D. Ringel, MD
Leonidas Duntas, MD	Emilio E. Lechuga, MD	Irving B. Rosen, MD
Mete Duren, MD	Elliot G. Levy, MD	Isadore N. Rosenberg, MD
Charles H. Emerson, MD	William J. Levy, MD	Libero Santarpia, MD, PhD
James A. Fagin, MD	Virginia A. LiVolsi, MD	David H. Sarne, MD
Jamshid Farahati, MD	Paul Margulies, MD	Jun Sasaki, MD, PhD
Alan P. Farwell, MD	M. Elizabeth Mason, MD	Martin Schlumberger, MD
Delbert A. Fisher, MD	Jane V. Mayrin, MD	Arthur B. Schneider, MD, PhD
Shuji Fukata, MD	Brooks B. Mays, MD	Kathryn G. Schuff, MD
Fumihiko Furuya, MD, PhD	Michael T. McDermott, MD	Harold L. Schwartz, PhD
	Sandra M. McLachlan, PhD	Steven I. Sherman, MD

*continued on next page*



# Thank You to Our Annual Fund Donors 2010

## 2010 ATA Annual Fund Donors, *continued*

Yoshimasa Shishiba, MD, PhD  
J. Enrique Silva, MD  
Peter A. Singer, MD  
J. Woody Sistrunk, MD  
David H. Solomon, MD  
Christopher Sonnier, MD  
Alex S. Stagnaro-Green, MD  
Elias M. Stephan, MD  
David Leland Steward, MD  
Kyoko M. Takeda, MD, PhD

Masahiro Takei, MD  
Michael J. Thomas, MD, PhD  
Yaron Tomer, MD, FACP, FACE  
Nagaoki Toyoda, MD  
R. Michael Tuttle, MD  
Hidemasa Uchimura, MD  
Robert Udelsman, MD  
Alvin L. Ureles, MD  
Stan H. Van Uum, MD, PhD  
Irina E. Veronikis, MD

Theo J. Visser, PhD  
Paul G. Walfish, MD  
Mikio Watanabe, MD, PhD  
Samuel Weisz, MD  
Thomas M. Wheeler, MD  
Craig Wierum, MD  
R. Bruce Wilcox, PhD  
Max V. Wisgerhof, II, MD  
Paul D. Woolf, MD, MBA, FACP  
Sing-yung Wu, MD, PhD

To make a contribution to the ATA Annual Fund, go to —  
[www.thyroid.org](http://www.thyroid.org)

### AMERICAN THYROID ASSOCIATION FELLOWS' CORNER

[www.thyroid.org/fellows.html](http://www.thyroid.org/fellows.html)

ATA's Fellows' Corner & website offers medical professionals and patients pertinent information combined with medical insight.

Explore the ATA website at [www.thyroid.org](http://www.thyroid.org) and see for yourself how helpful it is.

A resource designed with you in mind!



Visit the ATA Fellows' Corner at [www.thyroid.org/fellows.html](http://www.thyroid.org/fellows.html)

## “Find a thyroid specialist” is better able to find You!

Thanks to the efforts of the ATA Clinical Affairs Committee, led by Dr. Mira Milas, the ATA Physician Finder is easier to navigate, more intuitive, and has improved functionality. Please try out the tool by going to the ‘Find A Specialist’ link on the [ATA Home page \(www.thyroid.org\)](http://www.thyroid.org). Both ATA members and patients can now search for ATA physician specialists by specifying any of the following criteria:

- Physician Name or Institution
- U.S. State or City Location
- U.S. Zip Code, includes a radius search feature
- World/International Location
- Physician Specialty
- Physician Disorders Seen in Practice
- Physician Areas of Special Interest

To ensure you are included in the Physician Referral listing and your information is up-to-date, please log into the [Member Services](http://www.thyroid.org/services/login.php) section of the ATA website (<http://www.thyroid.org/services/login.php>) section of the website (you must be an Active or Senior Member of the ATA to be listed on physician referral).

Please review and update the information in the Personal and Address sections of your member profile, as well as the Physician Referral information which is located in the Demographics section of your profile. Be sure to:

- Check the Refer Patients checkbox
- Update your website address
- Add/update your Patient/Clinic Phone Number

If you have any questions regarding the physician finder or updating your information, please contact ATA Headquarters: [thyroid@thyroid.org](mailto:thyroid@thyroid.org) or (703) 998-8890.

---

### Corporate Leadership Council, *continued from page 1*

## We are creating the CLC with the mission to provide a forum for open communication between the ATA and the community of corporations that share interest in thyroid health and biology.

capacity to achieve our mission. In addition, we anticipate that improved relationships would contribute to the missions of our partners as well. To accomplish these critical strategic priorities, we are creating the CLC with the mission to provide a forum for open communication between the ATA and the community of corporations that share interest in thyroid health and biology.

The initial step in creating the Council will be held on May 14, 2010, during the Association’s Spring Meeting at the Hyatt Regency in Minneapolis, MN. At this session, the CLC will meet to discuss the needs and priorities of the potential corporate members as well as the Association, establish a membership and leadership structure for the Council, and formalize the outlines for future meetings. Participants from the ATA will include select officers, committee chairs, and members of the Board of Directors.

We look forward to this initial Council meeting and to working together in the pursuit of our common goals:

1. To promote transparent discussion among the medical, scientific, and business leadership of the participating corporations and the ATA on issues affecting thyroidology, including
  - a. prevention, detection, and treatment of thyroid disease,
  - b. research on thyroid molecular and cell biology, physiology, and diseases,

- c. education of physicians, scientists, and other health professionals, and
  - d. advocacy and public policy
2. To integrate industry trends and needs with strategic objectives of the ATA.
3. To foster partnerships and collaborations between the ATA and industry involving projects and services of common interest, while adhering to the highest ethical standards for such relationships.
4. To recognize and enhance the scientific and professional contributions of ATA members who work in industry.

The ATA CLC will function under the mission, vision, values, and goals of the ATA. In addition to adhering to the ATA Conflict of Interest and Code of Conduct Policy, the CLC will abide by the standards established by the Accreditation Council for Continuing Medical Education (ACCME), the AdvaMed guidelines, the American Medical Association’s Ethical Opinion on Continuing Medical Education and Gifts to Physicians, the Food and Drug Administration regulations regarding Industry-supported Scientific and Educational Activities, Office of Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers, and the PhRMA code on Interactions with Healthcare Providers.

members and non-members and includes a monitored site for clinical and basic science exchange. NING allows us to make sub-groups on this site.

At the 80th Annual Meeting in Palm Beach last year, the group decided to add a 4th statement to their goals, which now include:

- Recruit and retain more women ATA members.
- Increase women's visibility within ATA.
- Better address women's thyroid health topics at ATA and other meetings.
- Engage Women in Thyroidology through technology networks to promote professional and personal interaction.

WIT President, Frances Carr and WIT member, Stephanie Lee spearheaded the creation of the social media pages with ATA staff led by Kelly Hoff.

The Women in Thyroidology group of the ATA is celebrating the eighth anniversary of a special initiative begun in 2002 to increase participation by women in our wonderful society. The ATA thrives on close ties among members and a collegial atmosphere at the annual meeting. WIT welcomes participation by all members, especially Fellows (Associate members), and encourages women scientists and physicians to participate in the camaraderie and benefits offered by the

ATA. WIT is especially dedicated to welcoming new women to the annual meeting and to the ATA.

The social media group has invited individuals by email so that the link and password is unique to each person. Respond by linking through the message to the web-based "NING" social network created specifically for Women in Thyroidology. Let the ATA office know if you have not received your email invite to the NING Social Media site.


Fran Carr, president of WIT, says, "In 2002, the founding year of WIT, only 10% of our ATA members were women. Today, that number is 33%. Importantly, the camaraderie that is a hallmark of the ATA has been expanded through the networking, mentoring, and collegiality offered through WIT. Building upon our successful advancement of women physicians and scientists in the ATA, the goals of WIT now extend to enhancing our collaborations, communication, and networking through NING." She invites everyone to join WIT "in this exciting new adventure!"

WIT will be meeting in Minneapolis at the Hyatt Regency on Thursday, May 13, 2010 from 4:30 – 6:00 pm. The gathering is open to all attendees; members and non-members. Hope to see you there!




Attendees at 80th Annual Meeting in Palm Beach

### Number of Women Joining the ATA Annually (since 1990)



### ATA Membership Breakdown by Member Type and Gender







**American Thyroid Association Spring 2010 Meeting**  
**Thyroid Disorders in the Era of Personalized Medicine**  
**MAY 13-16, 2010 • HYATT REGENCY MINNEAPOLIS, MINNESOTA**

**REGISTRATION FORM**

Meeting details available at  
[www.thyroid.org](http://www.thyroid.org)

ALL REQUESTED INFORMATION MUST BE PROVIDED TO PROCESS REGISTRATION FORM. ALL FEES ARE IN US DOLLARS.

NAME: FIRST \_\_\_\_\_ MIDDLE \_\_\_\_\_ LAST \_\_\_\_\_ NICKNAME FOR BADGE \_\_\_\_\_

PROFESSIONAL TITLE \_\_\_\_\_ PROFESSIONAL DEGREE(S) (PLEASE CHECK ONE):  
 a.  MD b.  PhD c.  MD, PhD d.  RN/PA e.  DO f.  OTHER \_\_\_\_\_

ORGANIZATION \_\_\_\_\_

ADDRESS 1 \_\_\_\_\_ PLEASE SPECIFY:  HOME  OFFICE  OTHER \_\_\_\_\_

ADDRESS 2 \_\_\_\_\_

CITY \_\_\_\_\_ STATE/PROVINCE \_\_\_\_\_ ZIP CODE + 4 COUNTRY \_\_\_\_\_ IF OUTSIDE THE U.S., COUNTRY/CITY CODE \_\_\_\_\_

PHONE \_\_\_\_\_ FAX \_\_\_\_\_ E-MAIL ADDRESS \_\_\_\_\_

SPECIAL NEEDS/DIETARY RESTRICTIONS \_\_\_\_\_

EMERGENCY CONTACT: \_\_\_\_\_ DAYTIME PHONE: \_\_\_\_\_ EVENING PHONE: \_\_\_\_\_

**REGISTRATION CATEGORIES & FEES** (PLEASE CHECK APPLICABLE FEES):

	DISCOUNTED (received between March 15 – April 25)	FULL FEE (received after April 25)
(M) ATA MEMBER	<input type="checkbox"/> \$560	<input type="checkbox"/> \$595
(N) NON-MEMBER	<input type="checkbox"/> \$725	<input type="checkbox"/> \$795
ATA FELLOWS (ASSOCIATE MEMBERS)	<input type="checkbox"/> \$200	<input type="checkbox"/> \$200
Focus: <input type="checkbox"/> (AC)Clinical or <input type="checkbox"/> (AB)Basic		
NON-MEMBER FELLOWS/STUDENTS/RA*	<input type="checkbox"/> \$225	<input type="checkbox"/> \$225
Focus: <input type="checkbox"/> (NC)Clinical or <input type="checkbox"/> (NB)Basic <small>(*Verification req.; Send letter from Prog. Dir. to 703-998-8893 / <a href="mailto:thyroid@thyroid.org">thyroid@thyroid.org</a>)</small>		
(P) PRESS (VERIFICATION REQUIRED)	<input type="checkbox"/> \$0	<input type="checkbox"/> \$0

**DAILY REGISTRATION RATE**

(M) MEMBER	<input type="checkbox"/> \$325	<input type="checkbox"/> \$350
(N) NON-MEMBER	<input type="checkbox"/> \$450	<input type="checkbox"/> \$500
Indicate day(s): <input type="checkbox"/> (F) FRI 5/14 (includes Thursday Welcome Reception) <input type="checkbox"/> (S) Sat./Sun. 5/14 & 5/16		

(G) SPOUSE/GUEST  \$95  \$95  
*(Spouse/Guest registration admits attendee (with badge only) to the welcome reception, coffee breaks, exhibit hall and Spring banquet at reduced rate)*  
 (1) Spouse/Guest Name: \_\_\_\_\_  
 (2) Spouse/Guest Name: \_\_\_\_\_

(DS1) Do you want to participate in the "Bring A Colleague" Registration Discount of \$105 per registrant?  Yes  No  
(NOTE: Offer applies to one member/one non-member registration combination only—both registrants must register independently and provide the email address of the attendee they wish to share the discount with below.)  
 Bring a Colleague Partner Name: \_\_\_\_\_  
 Bring a Colleague Partner Email Address: \_\_\_\_\_

- I require a CME certificate for my attendance at this meeting.
- I consider myself primarily (please list one): \_\_\_\_\_  
 a. Clinician b. Educator c. Scientist d. Other: \_\_\_\_\_
- My work is best described as (please list one): \_\_\_\_\_  
 a. Endocrinology b. Nuclear Medicine c. Surgery  
 d. Internal Medicine e. Family Medicine f. Oncology  
 g. Other \_\_\_\_\_
- My place of work is (please list one): \_\_\_\_\_  
 a. Academic b. Private Practice c. Administration  
 d. Hospital e. Government/Military f. Corporate/Industry  
 g. Managed Care h. Other: \_\_\_\_\_
- What is your membership affiliation (other than ATA)?  
 a.  ENDO b.  AAES c.  AAO-HNS d.  LWPEP e.  AACPE  
 z.  Other: \_\_\_\_\_
- How did you hear about the ATA Annual Meeting?  
 a.  ATA Website b.  ATA E-mail c.  ATA Mailed Promotional Piece  
 d.  ATA Publication z.  Other: \_\_\_\_\_
- ATA Photo Release: ATA uses photographs of conference participants in our promotional materials and journals. By virtue of your attendance at this meeting, ATA reserves the right to use your likeness in such materials.

**MEET THE PROFESSOR WORKSHOPS**

Meet the Professor (MTP) workshops will be open to attendees at no charge on a first-come, first served basis. There is open seating during each time slot. There will be three workshops offered on Friday and Saturday. Please review the meeting agenda at [www.thyroid.org](http://www.thyroid.org) for MTP speaker names and topics.

**SPECIAL ACTIVITY REGISTRATION** (CHECK ALL THAT APPLY)

- \$325 (U1) ADVANCED ULTRASOUND LECTURE AND PRACTICUM  
THURSDAY, 5/13, 9:00 AM – 1:30 PM (Limited seating, 1st-come-1st-served basis)
- \$295 (U2) INTRODUCTORY HANDS-ON ULTRASOUND LECTURE AND PRACTICUM  
THURSDAY, 5/13, 12:45 – 6:00 PM (Limited seating, 1st-come-1st-served basis)
- \$0 (ACO) ATA Committee Meetings  
FRIDAY, 5/14, 12:45 – 1:30 PM (For current ATA committee members only)
- \$0 (WIT) Women in Thyroidology THURSDAY, 5/13, 4:30 – 6:00 PM
- \$0 (REC) ATA Welcome Reception THURSDAY, 5/13, 6:00 – 7:30 PM
- \$55 (BAN) Registered Attendees or Spouse/Guest–Spring Banquet Fee  
SATURDAY, 5/15, 7:30 – 11:00 PM (NOTE: (BNF) Registered Fellows' Rate is \$25)
- \$95 (BNQ) Non-Registered Attendees, Spouse/Guest or Press–Spring Banquet Fee  
SATURDAY, 5/15, 7:30 – 11:00 PM

**TOTAL FEES** (PLEASE TOTAL EACH LINE ITEM IF MORE THAN ONE):

\$ _____	Attendee Registration Fee (sum all appropriate fees here)	
\$ _____	Spouse/Guest Registration Fee (\$95 per guest)	
\$ _____	Introductory Ultrasound Lecture and Practicum (\$295)	# _____
\$ _____	Advanced Ultrasound Lecture and Practicum (\$325)	# _____
\$ _____	ATA Meeting Registrant–Spring Banquet Fee (\$55)	# _____
\$ _____	Registered Spouse/Guest–Spring Banquet Fee (\$55)	# _____
\$ _____	Non-Registered Attendee/Guest/Press–Banquet Fee (\$95)	# _____
\$ _____	Registered Fellows–Banquet Fee (\$25)	# _____
\$ _____	Donation to Fellows' Travel Fund	
\$ _____	<b>TOTAL DUE</b> (provide a check or credit card for this amount)	

**SUBMISSION AND PAYMENT**

- Checks and money orders for registration payable to the American Thyroid Association in U.S. dollars drawn on a U.S. bank.
- MasterCard  VISA  American Express

CARD NUMBER \_\_\_\_\_

EXPIRATION DATE (MONTH/YEAR) \_\_\_\_\_ 3 OR 4 DIGIT SECURITY CODE \_\_\_\_\_

PRINT CARDHOLDER'S NAME \_\_\_\_\_ SIGNATURE \_\_\_\_\_

**REGISTER ON-LINE** at the secure ATA web site [www.thyroid.org](http://www.thyroid.org).  
**FAX** completed form with credit card payment to 678-341-3081. If you **FAX**, DO NOT MAIL.  
**MAIL** your completed registration form with payment to: ATA Registration, c/o QMS, 6840 Meadowridge Court, Alpharetta, GA 30005. Phone: 678-341-3056.  
**ATA REFUND POLICY:** Refund requests must be submitted in writing (e-mail to [thyroid@thyroid.org](mailto:thyroid@thyroid.org)). Requests submitted by fax or e-mail before March 28, 2010, will receive a registration refund less a 50% processing fee. No refunds will be made if submitted after March 28, 2010. Refunds will be processed 30 days after the meeting.  
**Please keep a copy of this form for your records.**



**Ultrasound Workshops:**

Metastatic Lymph Nodes: Why They Matter  
 Ultrasound Evaluation of Lymph Nodes  
 Parathyroid Ultrasound  
 Cytology: Preparation and Interpretation

Physics of Ultrasound  
 Ultrasound of Thyroid Nodules  
 Ultrasound of Diffuse Thyroid Disorders  
 Ultrasound-Guided Fine-Needle Aspiration

**FACULTY:**

Jennifer Sipos  
 Susan J. Mandel  
 Stephanie A. Fish  
 Nicole A. Massoll

Stephanie A. Fish  
 Susan J. Mandel  
 Erik K. Alexander  
 Bryan R. Haugen

**Drug Screening for Personalized Medicine Using Mutated Drosophila**

Ross Cagan

**Genetic Markers and Personalized Diagnosis of FNA Samples**

Molecular Diagnostics in Thyroid FNA Samples  
 Prognostic Utility of BRAF Mutation in Papillary Thyroid Cancer  
 Personalized Follow-Up in Thyroid Cancer Using Tumor-Specific Genetic Markers

Yuri E. Nikiforov  
 Mingzhao Xing  
 Stefan K.G. Grebe

**Recent Developments in Thyroid Cancer**

Thyroid Microcarcinoma  
 Vitamin D and Thyroid Cancer  
 Familial Syndromes Associated with Thyroid Cancer

Bryan Haugen  
 Joshua Klopper  
 Melanie Richards

**Personalized Surgical Therapy for Thyroid Cancer**

Operative Management of Primary Papillary Thyroid Carcinoma  
 Clinical Considerations in Reoperative Surgery for Thyroid Cancer  
 Rationale for a Tailored Approach to Elective Central Neck Dissection  
 in Papillary Thyroid Cancer  
 Minimally Invasive Video Assisted Thyroidectomy

Clive S. Grant  
 Ralph P. Tufano

Christopher R. McHenry  
 David J. Terris

**Pediatric Thyroid Disease**

Pediatric Graves' Disease  
 Neonatal Hypothyroidism  
 Treatment of Papillary Thyroid Carcinoma in Children

Rosalind Brown  
 Robert Rapaport  
 Geoffrey Thompson

**Personalized Thyroid Cancer Treatment**

James Fagin

**Lessons Learned from Thyroiditis-Associated Autoimmune Disorders**

Genetic Studies of Vitiligo  
 Genetic Studies of Type 1 Diabetes  
 Hypophysitis

Richard Spritz  
 George Eisenbarth  
 Yaron Tomer

**Arthur Bauman Clinical Symposium: Immunogenetics, Epigenetics and Environmental Triggers of Autoimmune Thyroid Disorders**

TSH Receptor Variants in Graves' Disease  
 Genetics of Autoimmune Thyroid Disease and Type 1 Diabetes  
 Environmental Toxins and Autoimmune Thyroid Disease

Terry F. Davies  
 George Kahaly  
 Gregory Brent

**Drugs and Disorders of Thyroid Function: Overview**

Opportunistic Autoimmune Disorders Triggered by Immunotherapy  
 Amiodarone

Giuseppe Barbesino  
 Yi-chi Kong  
 Elizabeth Pearce

**Pharmacogenomics and Genetic Screening to Prevent Drug Reactions in Children**

Colin Ross

**Pregnancy, Postpartum and Thyroid Disease**

Assessment of Thyroid Function in Pregnancy  
 Management of Graves' Disease in Pregnancy  
 Postpartum Thyroiditis

Carole Spencer  
 Linda Barbour  
 Erin Keely

**Graves' Ophthalmopathy**

Risk Factors for Graves' Ophthalmopathy  
 Steroid Prophylaxis in Patients Receiving Radioactive Iodine Therapy  
 Future Therapies for Graves' Ophthalmopathy

Marius Stan  
 George Kahaly  
 Rebecca Bahn

**Meet the Professor Workshops**

*Ian D. Hay*  
 Remnant Ablation in Papillary Thyroid  
 Cancer: Time to Get More 'Personalized'

*Nancy Carrasco*  
 Update on Sodium Iodide  
 Symporters (NIS)

*Michael T. McDermott*  
 Risks of Radioactive Iodine  
 Treatment

*Ralph P. Tufano*  
 Reoperative Surgery for Well  
 Differentiated Thyroid Cancer: Pearls,  
 Pitfalls and Realistic Expectations

*Antonio C. Bianco*  
 Deiodinase Regulation  
 of Thyroid Hormone Action

*David S. Cooper*  
 Guidelines for Thyroid Nodules  
 and Differentiated Thyroid Cancer

# 2010 Thank You!

## Sponsor and Support Acknowledgements

The American Thyroid Association and The University of Colorado Denver School of Medicine wish to express sincere appreciation to the following companies for educational grants and other support for this meeting:

**Abbott Laboratories**  
Abbott Park, Illinois

**Ethicon Endo-Surgery, Inc.**  
Nokesville, Virginia

**Genzyme Corporation**  
Cambridge, Massachusetts

**KRONUS, Inc.**  
Boise, Idaho

**Onyx Pharmaceuticals and  
Bayer Healthcare  
Pharmaceuticals, Inc.**  
Emeryville, California

**Veracyte, Inc.**  
San Francisco, California

The American Thyroid Association and The University of Colorado Denver School of Medicine wish to express appreciation to the following companies for their commitment to continuing medical education by providing in-kind support for the ultrasound workshops at this meeting:

**GE Healthcare**  
Bemidji, Minnesota

**Mindray Ultrasound**  
Dixon, California

**SmartSound Ultrasound**  
Clermont, Florida

**SonoSite**  
Bothell, Washington

**Toshiba Ultrasound**  
Pleasanton, California

**Ultrasonix Medical  
Corporation**  
Richmond, British Columbia,  
Canada

*American Thyroid Association  
SPRING 2010 MEETING*

Thyroid Disorders in the  
Era of Personalized Medicine

## Upcoming Meetings

### 14th International Thyroid Congress

September 11-16, 2010  
Paris, Palais des Congrès

### 81st Annual Meeting of the American Thyroid Association

October 26-30, 2011  
The Renaissance Esmeralda  
Indian Wells, California

### 82nd Annual Meeting of the American Thyroid Association

September 19-23, 2012  
Hilton Quebec City  
Quebec City, PQ, Canada

### 83rd Annual Meeting of the American Thyroid Association

October 16-20, 2013  
Sheraton Puerto Rico Convention Center  
Hotel and Casino  
San Juan, Puerto Rico

### 84th Annual Meeting of the American Thyroid Association

October 29 - November 2, 2014  
Hotel del Coronado  
Coronado, California

### 15th International Thyroid Congress (Hosted by the American Thyroid Association)

September 17-23, 2015  
Walt Disney World Swan  
and Dolphin Resort  
Orlando, Florida

### 85th Annual Meeting of the American Thyroid Association

September 21-25, 2016  
Sheraton Denver Downtown Hotel  
Denver, Colorado

[www.thyroid.org](http://www.thyroid.org)